BiotechTube

ASP1893

Phase 1Withdrawn
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CLDN6-positive Solid Tumor

Conditions

CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Testicular Cancer, Metastatic or Locally Advanced Solid Tumor Cancer

Trial Timeline

Dec 31, 2024 → Mar 31, 2029

NCT ID
NCT06681870

About ASP1893

ASP1893 is a phase 1 stage product being developed by Astellas Pharma for CLDN6-positive Solid Tumor. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06681870. Target conditions include CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06681870Phase 1Withdrawn

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85